Ken Griffin Homology Medicines, Inc. Call Options Transaction History

Citadel Advisors LLC

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2023 Feb 14, 2024	BUY	$0.53 - $1.14 $212 - $455	400 Added 13.33%	3,400 $2,000
Q3 2023 Nov 14, 2023	SELL	$0.84 - $1.43 $18,144 - $30,888	-21,600 Reduced 87.8%	3,000 $3,000
Q2 2023 Aug 14, 2023	BUY	$0.83 - $1.12 $2,075 - $2,800	2,500 Added 11.31%	24,600 $21,000
Q1 2023 May 15, 2023	BUY	$0.91 - $1.69 $91 - $169	100 Added 0.45%	22,100 $22,000
Q4 2022 Feb 14, 2023	BUY	$1.09 - $2.04 $11,881 - $22,236	10,900 Added 98.2%	22,000 $27,000
Q3 2022 Nov 14, 2022	BUY	$1.55 - $3.01 $17,205 - $33,411	11,100 New	11,100 $18,000

66.2K

Ticker FIXX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 57,402,000
Description
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nucleas...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.